Recursion

Recursion is a biopharmaceutical company leveraging new technology to create virtuous cycles of learning around datasets, aiming to build a next-generation biopharmaceutical enterprise. The company manages more than 50 petabytes of proprietary biological, chemical, and patient-centric data and conducts up to 2.2 million wet lab experiments profiling genes and compounds per week. Recursion operates BioHive-1, one of the top 500 supercomputers across any industry, and produces over 50 cell types at scale, including more than 1 trillion hiPSC-derived neuronal cells. It has profiled over 6 trillion gene and compound relationships in their Maps and is a founding member of BioHive, the fastest growing life sciences community in the nation. Recursion’s headquarters is located at 41 S Rio Grande Street, Salt Lake City, UT 84101. The company aims to become net-zero in greenhouse gas emissions by 2030 and achieve equal gender representation by the same year. Recursion directs 1% of its equity into the Recursion Foundation, which supports sustainable, diverse, and equitable life science and technology hubs and expands STEM education opportunities for diverse youth. The company’s LLM-orchestrated Workflow Engine, LOWE, supports drug discovery programs by orchestrating complex workflows and integrates with the Recursion OS, providing access to extensive proprietary data and specialized computational tools. Recursion collaborates with NVIDIA to accelerate the development of AI foundation models for biology and chemistry, with Bayer to identify novel therapeutics for fibrotic diseases and precision oncology programs, with Tempus to access one of the world’s largest proprietary, de-identified, patient-centric oncology datasets, and with Enamine to generate and design enriched compound libraries for the global drug discovery industry. Recursion’s drug discovery pipeline includes programs in rare diseases and precision oncology, with ongoing clinical trials such as the Phase 2 SYCAMORE trial for REC-994 in Cerebral Cavernous Malformation, the Phase 2/3 POPLAR trial for REC-2282 in NF2-mutated meningiomas, the Phase 2 TUPELO trial for REC-4881 in Familial Adenomatous Polyposis, and an upcoming Phase 2 proof-of-concept trial for REC-3964 to treat Clostridioides difficile infection. Recursion’s integrated system, Recursion OS, generates, analyzes, and derives insights from massive biological and chemical datasets. The company’s proprietary dataset, RxRx, aggregates over time to enhance experimentation speed and quality. Tools like PhenoMap, Scaffold Shopper, and Phenom-Beta model support drug discovery by inferring relationships among biological perturbations, comparing candidate compounds, and processing microscopy images into general-purpose embeddings.